Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

What happened: Roche reported phase III Krascendo 1 results showing divarasib, an investigational next-generation KRAS G12C inhibitor, beat sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC. Why it matters: Roche said the head-to-head trial reinforces divarasib's best-in-class profile and it is working with health authorities on bringing the treatment to patients. The study lead author called the results practice-changing.

Roche reported phase III Krascendo 1 results showing divarasib, an investigational next-generation KRAS G12C inhibitor, beat sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC.

Roche said the head-to-head trial reinforces divarasib's best-in-class profile and it is working with health authorities on bringing the treatment to patients. The study lead author called the results practice-changing.